Key result
Novel RNA-seq pipeline identifies ~43,000 high-quality SNVs and putative pathogenic variants in HCM myocardial tissue.
Why the study?
RNA-seq can be used to identify single nucleotide variations, but studies using modern RNA-seq specific alignment methods in hypertrophic cardiomyopathy are uncommon.
Cohort (n=48)
RNA-seq can be effectively used to identify single nucleotide variations and putative pathogenic variants in myocardial tissue from patients with hypertrophic cardiomyopathy.
Supports RNA-seq for SNV detection in HCM myocardium; leaves open validation of novel candidates before clinical use.
A variety of techniques for DNA sequencing, such as specific gene sequencing, whole genome sequencing, or exome sequencing, are currently used to detect single nucleotide variations (SNVs). Although RNA-seq can be used to identify SNVs, studies that employ this approach are uncommon, and those that do often rely on outdated mapping methods or methods that are more suitable for genomic and exomic alignment. In this work, our aim is to apply modern RNA-seq specific alignment method in order to identify SNV in a cohort of HCMP patients, and characterize those SNV to gain insight into possible mechanisms of HCMP pathogenesis. The algorithm of identification of SNV based on transcriptomic sequencing data has been developed and evaluated. The algorithm was evaluated and the optimal quality threshold was determined based on allelic discrimination for the rs397516037 mutation (MYBPC3 c.3697 C > T) among patients. A total of 42,809 SNVs with a quality of 75 or higher were identified in 48 transcriptomes of hypertrophic cardiomyopathy (HCMP) myocardial tissue. Verification of missense and nonsense variants in key HCMP genes using Sanger sequencing confirmed the accuracy of the pipeline results. To identify variants potentially associated with HCMP pathogenesis, a filtration process was conducted based on minor allele frequency, substitution prediction score and ClinVar outcome. 214 missense mutations and 6 nonsense mutations were selected. Together with nonsense mutations, 19 mutations meeting the strictest SIFT and PolypPhen criteria were identified as potential factors influencing HCMP pathogenesis. We have developed and validated a method for identifying SNVs based on transcriptomic data, which can be used to identify putative pathogenic variants. We identified mutations in key HCMP genes MYBPC3 and MYH7 in a cohort of patients. We also found potentially pathologic mutations in genes ANXA6 and FEM1 A and obtained data supporting the role of NEBL in myocardial diseases. This method would be useful in analyzing transcriptomic data available in the Gene Expression Omnibus, but should be used with caution as we have tested it on a specific disease.
No takes yet. Share an insight, caveat, or question.
Chumakova et al. (2025) conducted a cohort in Hypertrophic cardiomyopathy (n=48). RNA sequencing (RNA-seq) was evaluated on Identification of high-quality single nucleotide variations (SNVs). A novel RNA-seq pipeline applied to myocardial tissue from 48 hypertrophic cardiomyopathy patients successfully identified 42,809 high-quality SNVs, including putative pathogenic variants in MYBPC3, MYH7, ANXA6, and FEM1A.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: